

## Lovastatin Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)

### [ Product Information ]

**Name:** Lovastatin


**Catalog No.:** CFN99961

**Cas No.:** 75330-75-5

**Purity:** >=98%

**M.F:** C<sub>24</sub>H<sub>36</sub>O<sub>5</sub>

**M.W:** 404.54



**Physical Description:** Powder

**Synonyms:** (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate.

### [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

### [ Source ]

From *Aspergillus terreus*.

### [ Biological Activity or Inhibitors ]

Lovastatin reduces the risk for the first acute major coronary event in men and women with average total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and below-average high-density lipoprotein cholesterol (HDL-C) levels, these findings support the inclusion of HDL-C in risk-factor assessment, confirm the benefit of LDL-C reduction to a target goal, and suggest the need for reassessment of the National Cholesterol Education Program guidelines regarding pharmacological intervention.<sup>[1]</sup>

Lovastatin can potentiate the chemopreventive effects of sulindac against colon neoplasia in a rodent model and augments apoptosis induced by 5-FU and cisplatin in human colon cancer cells; lovastatin induces morphologic changes and apoptosis by inhibiting geranylgeranylation of small GTPases of the rho family and thereby inactivating them.<sup>[2]</sup>

Lovastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (the major regulatory enzyme of the mevalonate pathway of cholesterol synthesis), displays antitumor activity in experimental models. <sup>[3]</sup>

Lovastatin has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy, at least in part, through suppression of glomerular expression of Transforming growth factor-beta (TGF-beta)1.<sup>[4]</sup>

### **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

### **[ HPLC Method ]<sup>[5]</sup>**

Mobile phase: 0.05 M Phosphate buffer (pH 7)- Acetonitrile =44.5 : 55.5 ;

Flow rate: 1.0 ml/min;

Column temperature: Room Temperature;

The wave length of determination: 238 nm.

### **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

- [1] Downs J R, Clearfield M, Weis S, *et al.* *Jama J. Am.Med. Assoc.*, 1998, 279(20): 1615-22.
- [2] Agarwal B, Halmos B, Feoktistov A S, *et al.* *Carcinogenesis*, 2002, 23(3):521-8.
- [3] Thibault A, Samid D, Tompkins A C, *et al.* *Clinical Cancer Research An Official Journal of the American Association for Cancer Research*, 1996, 2(3):483-91.
- [4] Kim S I, Han D C, Lee H B. *J. Am. Soc. Nephrol.*, 2000, 11(1):80-7.
- [5] Hirata M. *Biol. Pharm.Bull.*, 2009, 32(9):1600-3.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)